ANDA Submission Consulting

Reduce ANDA submission timelines and operational costs while maintaining expert regulatory oversight.

Accelerate ANDA Development with Regulatory Expertise and AI-Driven Efficiency

Successful ANDA submissions require more than technical documentation; they require regulatory strategy, submission excellence, and a deep understanding of FDA expectations.

ProPharma combines regulatory expertise with an AI-enabled submission platform to help generic drug sponsors streamline ANDA preparation, reduce operational burden, and accelerate submission readiness without compromising quality or compliance.

From first-time filers to established generic manufacturers, we provide the strategic guidance, technical expertise, and scalable support needed to move confidently from development to approval.

The ProPharma Difference: Expertise Enhanced by Innovation

Successful ANDA submissions require more than speed. They demand regulatory expertise, scientific rigor, and a clear understanding of FDA expectations.

Our proprietary approach to generic drug development combines experienced regulatory professionals with a novel AI-driven approach designed to improve efficiency without compromising quality. Our technology helps streamline document development, enhance consistency, and reduce manual effort, while our experts provide the strategic guidance, scientific review, and regulatory oversight needed to support submission success.

This expert-led, AI-enabled model helps sponsors:

Accelerate submission timelines
Improve consistency and quality across application components
Reduce operational burden on internal teams
Scale submission activities more efficiently
Maintain confidence in regulatory compliance and submission readiness

Backed by former FDA professionals, CMC specialists, regulatory strategists, medical writers, and publishing experts, our team delivers the expertise and innovation needed to navigate ANDA submissions with greater speed,

Comprehensive ANDA Submission Support

From development planning through FDA review and approval, our team provides end-to-end support across the ANDA lifecycle.

Regulatory Strategy and Submission Planning

A successful ANDA begins with a clear regulatory strategy. Our experts help sponsors identify risks early, align development activities with FDA expectations, and establish an efficient path to submission.

Services include:

Regulatory pathway assessment
ANDA development strategy
FDA regulatory intelligence
Gap assessments and readiness evaluations
Submission planning and risk mitigation

ANDA Authoring, Publishing, & Submission Management

Our team supports the preparation, review, compilation, and publishing of high-quality ANDA submissions designed to facilitate efficient FDA review.

Services include:

Technical and scientific writing
Submission-ready document development
Content review and quality control
Submission compilation and management
eCTD publishing support

CMC and Bioequivalence Support

ProPharma provides integrated technical support across CMC and bioequivalence activities, helping sponsors develop, document, and present critical data required for ANDA success.

Services include:

CMC strategy and documentation
Drug substance and drug product support
Manufacturing and facility information
Bioequivalence strategy
Technical data review and regulatory assessment
Submission integration and quality review

FDA Review, Deficiency Response, & Lifecycle Management

Our support extends beyond submission. We help sponsors navigate FDA interactions, respond to agency requests, and manage post-submission activities through approval and beyond.

Services include:

FDA correspondence management
Information request responses
Deficiency response preparation
Complete Response Letter (CRL) remediation
Post-approval regulatory support
Lifecycle CMC and submission management

Supporting Generic Drug Sponsors Across the Product Lifecycle

Our team of expert regulatory consultants supports organizations at every stage of generic drug development, including:

Emerging pharmaceutical companies
Generic drug manufacturers
Specialty pharmaceutical organizations
Contract development and manufacturing organizations (CDMOs)
Global companies entering the US market

Whether you need support for a single submission or an ongoing regulatory partner, our team can scale to meet your needs.

Partner With Us

Several business professionals having fun at a business meeting

Why Partner with ProPharma?

Casually worker business professionals collaborating at a conference table

Successful ANDA submissions require the right combination of expertise, strategy, and execution.

Sponsors choose ProPharma because we offer:

Deep FDA and generic drug expertise
Former FDA professionals and industry leaders
Integrated regulatory, CMC, and submission capabilities
Proprietary AI-enabled efficiencies with expert oversight
Flexible support models tailored to your organization
End-to-end support from planning through approval

Our team helps sponsors reduce regulatory risk, improve operational efficiency, and accelerate the path to approval.

Speak with an Expert

Ready to Accelerate Your ANDA Submission?

Whether you are preparing your first ANDA or seeking a more efficient approach to managing submission volume, ProPharma can help. Connect with our Regulatory Sciences experts to discuss your program, timeline, and regulatory objectives.

ProPharma: The World's Leading Regulatory Consultancy

Contact us today to discuss your case and learn how our experts can strengthen your ANDA submission increasing efficiency and reducing the costs of application development.

Speak with an Expert

News & Insights

Thought Leadership Webinars Press Awards Resource Library

June 29, 2026

Responsible AI in Medical Information: Safety, Ownership, Oversight

Explore the critical role of responsible AI in medical information, focusing on safety, data ownership, and oversight to enhance patient care and trust.ca

Read Full Article

June 25, 2026

FAQ: In Vitro Diagnostics (IVDs)

Explore emerging trends in in vitro diagnostics (IVDs), from point-of-care testing and miniaturized diagnostics to wearable technologies and evolving regulatory considerations.

Read Full Article

June 22, 2026

A Risk-Based Road Map for Implementing AI

Discover a risk-based approach to implementing AI in life sciences, ensuring compliance, transparency, and governance throughout the entire lifecycle.

Read Full Article

View all Thought Leadership

June 18, 2026

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...

ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.

Read Full Article

May 27, 2026

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

ProPharma announces Adrian Pencak as Chief Commercial Officer, bringing 25 years of leadership experience to enhance global commercial capabilities and client partnerships.

Read Full Article

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

Read Full Article

View all Press

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

Read Full Article

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

Read Full Article

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Read Full Article

View all Awards

Case Study

June 17, 2026

Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sen...

Conducting clinical research for rare pediatric populations presents unique operational challenges, particularly when eligible patients may be born anywhere in the world and require immediate...

Read Full Article

Case Study

June 10, 2026

Accelerating Commercial Readiness for a Novel Cell Therapy Program

As advanced therapy developers move from research-stage operations toward commercialization, they often face significant challenges in scaling quality systems, aligning regulatory strategy, and...

Read Full Article

Case Study

May 20, 2026

Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed

When patient enrollment rapidly exceeds expectations, clinical trials can face significant operational strain, putting data integrity, timelines, and critical sponsor decisions at risk. A mid-size...

Read Full Article

View all Resources

June 4, 2026

Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery

Artificial intelligence (AI) is a hot topic in Medical Information (MI), yet real-world evidence of its impact in regulated, human-led MI environments remains limited. Hear practical, evidence-based...

Watch the Replay

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Watch the Replay

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

Watch the Replay

View all Webinars

News & Insights

June 29, 2026

Responsible AI in Medical Information: Safety, Ownership, Oversight

Explore the critical role of responsible AI in medical information, focusing on safety, data ownership, and oversight to enhance patient care and trust.ca

Read This Article

June 25, 2026

FAQ: In Vitro Diagnostics (IVDs)

Explore emerging trends in in vitro diagnostics (IVDs), from point-of-care testing and miniaturized diagnostics to wearable technologies and evolving regulatory considerations.

Read This Article

June 22, 2026

A Risk-Based Road Map for Implementing AI

Discover a risk-based approach to implementing AI in life sciences, ensuring compliance, transparency, and governance throughout the entire lifecycle.

Read This Article

June 18, 2026

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...

ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.

Read This Article

May 27, 2026

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

ProPharma announces Adrian Pencak as Chief Commercial Officer, bringing 25 years of leadership experience to enhance global commercial capabilities and client partnerships.

Read This Article

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

Read This Article

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

Read This Article

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

Read This Article

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Read This Article

Case Study

June 17, 2026

Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sen...

Conducting clinical research for rare pediatric populations presents unique operational challenges, particularly when eligible patients may be born anywhere in the world and require immediate...

View This Resource

Case Study

June 10, 2026

Accelerating Commercial Readiness for a Novel Cell Therapy Program

As advanced therapy developers move from research-stage operations toward commercialization, they often face significant challenges in scaling quality systems, aligning regulatory strategy, and...

View This Resource

Case Study

May 20, 2026

Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed

When patient enrollment rapidly exceeds expectations, clinical trials can face significant operational strain, putting data integrity, timelines, and critical sponsor decisions at risk. A mid-size...

View This Resource

June 4, 2026

Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery

Watch the Replay

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Watch the Replay

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

Watch the Replay